Veracyte CAO granted 10,525 restricted shares

Wygant Jonathan reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Wygant Jonathan reported acquisition or exercise transactions in this Form 4 filing.

VERACYTE, INC. reported that its VP and Chief Accounting Officer, Jonathan Wygant, received an equity award in the form of 10,525 shares of common stock on March 6, 2026. The shares were granted at no cash cost to him as part of compensation.

According to the award terms, these restricted stock units vest 25% on March 2, 2027, then 1/16 of the grant vests each quarter after that date, subject to his continued employment on each vesting date. Following this award, he directly holds 45,434 shares of Veracyte common stock.

Insider Trade Summary

Grant/Award: 10,525 shares

Grant/Award 1 txn

Insider Wygant Jonathan

Role VP, Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,525	$0.00	$0.00

Holdings After Transaction: Common Stock — 45,434 shares (Direct)

Footnotes (1)

1. F1. Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VERACYTE (VCYT) report for Jonathan Wygant?

VERACYTE reported that VP and Chief Accounting Officer Jonathan Wygant received a grant of 10,525 shares of common stock as compensation. The award is structured as restricted stock units that vest over time, rather than a cash purchase on the open market.

How many VERACYTE (VCYT) shares does Jonathan Wygant hold after this Form 4?

After this equity grant, Jonathan Wygant directly holds 45,434 shares of VERACYTE common stock. This total reflects his position immediately following the 10,525-share award reported, giving investors a snapshot of his current direct ownership stake.

What are the vesting terms of Jonathan Wygant’s 10,525 VERACYTE (VCYT) RSUs?

The 10,525 restricted stock units vest 25% on March 2, 2027, with the remaining portion vesting in 1/16 increments each quarter thereafter. Vesting is conditioned on Wygant’s continued employment on each scheduled vesting date.

Did Jonathan Wygant buy VERACYTE (VCYT) shares on the market in this filing?

No, the Form 4 shows a compensation-related grant coded as an acquisition, not an open-market purchase. The 10,525 shares were awarded at a price of $0.0000 per share as restricted stock units, subject to future vesting conditions.

Is the VERACYTE (VCYT) Form 4 for Jonathan Wygant a routine equity award?

The filing describes a grant coded as a grant or award acquisition, which is typical of equity compensation for executives. The structured vesting schedule over several years is consistent with standard retention-focused stock unit programs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 05:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wygant Jonathan

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		A(1)		10,525	A	$0	45,434	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

Remarks:

	/s/ Jonathan Wygant	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.